Replies to post #114354 on Biotech Values

[EyeamBill]

While it is somewhat farfetched

I've actually been part of (a.k.a, a victim of) such a strategy; though, not in the public arena (though one party was a public company). It's not as far-fetched as you might think, with the exception of the FTC.

Bill

[exwannabe]

While it is somewhat farfetched, I wouldn't put it past Teva if they looked to buy Momenta and fund the whole transaction by selling Momenta's portion of the copaxone franchise to Sandoz.

That would also not fly by the FTC/DoJ very well. You are still putting the only 2 potential Copox products in the same hands.

EDIT: Miss-read your post, I agree that would work but why would TEVA care to do so?